147 related articles for article (PubMed ID: 30916604)
21. Innate Immunity in Hepatitis C Virus Infection.
Schwerk J; Negash A; Savan R; Gale M
Cold Spring Harb Perspect Med; 2021 Feb; 11(2):. PubMed ID: 32341066
[TBL] [Abstract][Full Text] [Related]
22. Estrogen-related MxA transcriptional variation in hepatitis C virus-infected patients.
Mekky RY; Hamdi N; El-Akel W; Esmat G; Abdelaziz AI
Transl Res; 2012 Mar; 159(3):190-6. PubMed ID: 22340769
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis C virus-mediated enhancement of microRNA miR-373 impairs the JAK/STAT signaling pathway.
Mukherjee A; Di Bisceglie AM; Ray RB
J Virol; 2015 Mar; 89(6):3356-65. PubMed ID: 25589644
[TBL] [Abstract][Full Text] [Related]
24. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.
Aregay A; Owusu Sekyere S; Deterding K; Port K; Dietz J; Berkowski C; Sarrazin C; Manns MP; Cornberg M; Wedemeyer H
J Hepatol; 2019 Nov; 71(5):889-899. PubMed ID: 31295532
[TBL] [Abstract][Full Text] [Related]
25. Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure.
Colpitts CC; Baumert TF
Viruses; 2016 Aug; 8(8):. PubMed ID: 27537906
[TBL] [Abstract][Full Text] [Related]
26. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
27. Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection.
Zeisel MB; Crouchet E; Baumert TF; Schuster C
Viruses; 2015 Nov; 7(11):5659-85. PubMed ID: 26540069
[TBL] [Abstract][Full Text] [Related]
28. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
Halfon P; Sarrazin C
Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
[TBL] [Abstract][Full Text] [Related]
29. Interferons and hepatitis C virus.
Heim MH
Swiss Med Wkly; 2012; 142():w13586. PubMed ID: 22573217
[TBL] [Abstract][Full Text] [Related]
30. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
Asselah T; Marcellin P
Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
[TBL] [Abstract][Full Text] [Related]
31. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
32. [Antiviral treatment of chronic hepatitis C].
Berger A
Med Monatsschr Pharm; 2012 Feb; 35(2):55-60. PubMed ID: 22400430
[TBL] [Abstract][Full Text] [Related]
33. Polymorphism in interferon λ3/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy.
Khan AJ; Saraswat VA; Ranjan P; Parmar D; Negi TS; Mohindra S
J Med Virol; 2019 Apr; 91(4):659-667. PubMed ID: 30431653
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity.
Ding Q; Cao X; Lu J; Huang B; Liu YJ; Kato N; Shu HB; Zhong J
J Hepatol; 2013 Jul; 59(1):52-8. PubMed ID: 23542348
[TBL] [Abstract][Full Text] [Related]
35. Immunogenetic studies of the hepatitis C virus infection in an era of pan-genotype antiviral therapies - Effective treatment is coming.
Ellwanger JH; Kaminski VL; Valverde-Villegas JM; Simon D; Lunge VR; Chies JAB
Infect Genet Evol; 2018 Dec; 66():376-391. PubMed ID: 28811194
[TBL] [Abstract][Full Text] [Related]
36. Interferon-Mediated Cytokine Induction Determines Sustained Virus Control in Chronic Hepatitis C Virus Infection.
Wandrer F; Falk CS; John K; Skawran B; Manns MP; Schulze-Osthoff K; Bantel H
J Infect Dis; 2016 Mar; 213(5):746-54. PubMed ID: 26503984
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control.
Larrubia JR; Moreno-Cubero E; Miquel J; Sanz-de-Villalobos E
World J Gastroenterol; 2015 Mar; 21(12):3480-91. PubMed ID: 25834312
[TBL] [Abstract][Full Text] [Related]
38. Benefits of hepatitis C cure with antivirals: why test and treat?
Lledó G; Benítez-Gutiérrez L; Arias A; Requena S; Cuervas-Mons V; de Mendoza C
Future Microbiol; 2019 Mar; 14():425-435. PubMed ID: 30900911
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis C virus (HCV) employs multiple strategies to subvert the host innate antiviral response.
Bode JG; Brenndörfer ED; Häussinger D
Biol Chem; 2008 Oct; 389(10):1283-98. PubMed ID: 18713016
[TBL] [Abstract][Full Text] [Related]
40. Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice.
Blindenbacher A; Duong FH; Hunziker L; Stutvoet ST; Wang X; Terracciano L; Moradpour D; Blum HE; Alonzi T; Tripodi M; La Monica N; Heim MH
Gastroenterology; 2003 May; 124(5):1465-75. PubMed ID: 12730885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
